From digital dollars to hemp amendments and pre-roll power, here’s how Trump’s win is rewriting the cannabis playbook.
Dive into cannabis's crossroads—balancing distress and opportunity, women cultivating change at home, and new horizons in research and global policy shifts.
Shareholder Lawsuits, AG Drama, and Q3 Results Light Up This Week’s Cannabis News
Gabbard’s nod brings hope, Rubio’s raises concerns & more Q3 gains and pains
Trump’s pro-cannabis pick for AG, Belushi’s challenge to Big Pharma, and Q3 earnings reveal who’s cashing in and who’s falling behind.
Chris Christie suggests that Trump might reclassify cannabis, fueling investor optimism and boosting stocks in hopes of federal reform and market expansion.
From Colorado's cannabis paradox to Puerto Rico’s promising growth, plus the surge in demand for psychedelics therapy and Germany’s shifting policy landscape.
From veterans turning to psychedelics for PTSD to cannabis stocks reeling post-election and Puerto Rico’s promising market expansion, here’s what you need to know.
RFK Jr. shakes up the health agenda, Red Mesa cuts costs, and Jaunty redefines the game—insights and strategies you need this weekend.
Earnings flood reveals highs and lows in cannabis—top players tackle market hurdles, bold moves, and potential rebounds.
From Florida’s halt to Dallas’s green light, here’s where cannabis reform stands after last night’s votes.
As America votes, cannabis faces pivotal choices: from Florida hemp donors backing anti-weed stance and DEA hearings to shifting profit margins, here’s what’s at stake for the industry.
